Plain-English translation of NCT05625724 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a common medication, can help prevent preeclampsia (a serious high blood pressure condition that can develop during pregnancy) in first-time pregnant women who became pregnant through fertility treatments like IVF. About half of participants will take a low-dose pill daily, and half will take a placebo (a pill with no active medicine). Researchers want to see if this medication can reduce the risk of dangerous pregnancy complications.
Preeclampsia is a serious condition that affects about 2 in 100 pregnancies and can harm both the mother and baby. First-time pregnant women who used fertility treatment have an even higher risk — up to 10 in 100. While the medication has been shown to help prevent this condition in some high-risk women, doctors don't yet know if it works well for first-time pregnant women after fertility treatment, so this study aims to find out.
You likely qualify if…
You likely don't qualify if…
You will take one pill by mouth each evening starting between 9 and 14 weeks of pregnancy and continuing until 35-36 weeks of pregnancy (or until you deliver if earlier). Half of participants receive and half receive a placebo — neither you nor the researchers will know which pill you're taking. You will attend regular prenatal care visits where doctors monitor your health and your baby's development, as they normally would for any pregnancy.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
France